Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial

AIMS: Tofacitinib is an oral, small molecule JAK inhibitor being investigated for ulcerative colitis (UC). In a phase 2 dose‐ranging study, tofacitinib demonstrated efficacy vs. placebo as UC induction therapy. In this posthoc analysis, we aimed to compare tofacitinib dose and plasma concentration a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Arnab, Hazra, Anasuya, Smith, Mike K., Martin, Steven W., Mould, Diane R., Su, Chinyu, Niezychowski, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980553/
https://www.ncbi.nlm.nih.gov/pubmed/29377257
http://dx.doi.org/10.1111/bcp.13523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980553/
https://www.ncbi.nlm.nih.gov/pubmed/29377257
http://dx.doi.org/10.1111/bcp.13523

Ejemplares similares